Nanotherapy to control transmission and systemic infection caused by Candidozyma auris

Danilo Henrique Ramos – Doctoral, Microbiology, Institute of Biomedical Sciences, ICB II, University of São Paulo - USP; Martha Helena Chaves Magalhães – Doctoral, Microbiology, Institute of Biomedical Sciences, ICB II, University of São Paulo - USP; Carlos Pelleschi Taborda – Profesor, Microbiology, Institute of Biomedical Sciences, ICB II, University of São Paulo - USP

Poster Presenter(s)

Gabriel Davi Marena, Sr., Dr.

Posdoctoral
Institute of Biomedical Sciences, ICB II, University of São Paulo
São PAULO, Sao Paulo, Brazil

Introduction:

The increase in diseases caused by resistant fungi is alarmingly growing, to the point that the World Health Organization has issued a list of critical priority fungi, including Candidozyma auris. In this context, nanomedicine can contribute to the development of safer, more effective, and selective therapies, improving the therapeutic potential against these infections (1,2). Therefore, this study developed a chitosan nanoparticle (Nq) to subsequently (ongoing study) encapsulate a monoclonal antibody against ALS3, protein present in the cell wall of C. auris and contributing to the control of fungal adhesion to surfaces.

Learning Objectives:

determine the physicochemical conditions of a chitosan nonparticle for application on abiotic medical surfaces.
to establish the conditions for stability and factors that may interfere, such as temperature and pH.
To develop a nanoparticle capable of encapsulating a antibody against the surface protein of Candidozyma auris.